Tissue inhibitor of metalloproteinases 2–Matrix metalloproteinase 2 protein–protein interface (TIMP2–MMP2 interface)

The Tissue inhibitor of metalloproteinases 2–Matrix metalloproteinase 2 (TIMP2–MMP2) protein–protein interface is a specialized regulatory site involved in the activation of the latent enzyme proMMP2 [1.2.1, 1.3.2]. Unlike the inhibitory interaction where TIMP2 binds the MMP2 catalytic site, this interface involves the C-terminal hemopexin domain of proMMP2 and the C-terminal domain of TIMP2 [1.4.1, 1.4.2]. This specific interaction is required to form a ternary complex with membrane-type 1 MMP (MT1-MMP), which then facilitates the proteolytic cleavage and activation of proMMP2 on the cell surface [1.3.2, 1.4.4]. Because this mechanism is unique to MMP2, targeting this interface allows for highly selective modulation of MMP2 activity, avoiding the broad-spectrum inhibition that led to the failure of earlier MMP-targeting drugs [1.2.1, 1.2.2]. Pathological overactivation of MMP2 via this interface is a hallmark of cancer metastasis, angiogenesis, and inflammatory diseases like atherosclerosis and fibrosis [1.3.1, 1.4.2]. Research has led to the development of cyclic peptides, such as cy(WPHPY), which bind to the D570-A583 epitope on the proMMP2 hemopexin domain to sterically hinder the TIMP2-proMMP2 interaction [1.2.2, 1.2.3]. By preventing the assembly of the activation complex, these agents effectively inhibit the migration and invasion of malignant cells [1.2.1, 1.3.1]. This approach represents a significant shift toward precision medicine in the field of metalloproteinase inhibition, aiming to reduce systemic toxicities like musculoskeletal syndrome while maintaining therapeutic efficacy [1.2.2, 1.4.1].

Other names

TIMP2-proMMP2 complexTIMP2-MMP2 PPIproMMP2-TIMP2 interactionTIMP-2/MMP-2 interface

Inhibition of proMMP2 activation by disrupting the protein-protein interaction between the proMMP2 hemopexin domain and the TIMP2 C-terminal domain